Cannabis User
Conditions
Brief summary
The endocannabinoid system (ECS) is a complex endogenous signaling system made up of transmembrane cannabinoid receptors (CB1 and CB2 receptors), their endogenous lipid-derived ligands (the endocannabinoids - eCBs), and enzymes for ligand biosynthesis and degradation. Interestingly, exercise increase plasma AEA, one of the most famous endocannabinoid. This increase could be involved in exercise-induced neurogenesis and other beneficial exercise adaptations. Chronic cannabis use is associated with alteration of ECS activity. The aim of the study is to compare ECS response to exercise between chronic cannabis users and non-users.
Interventions
OTHERactivity test
Over 2 weeks, participants have to do a maximal progressive exercise and a 30 min constant exercise at 50% of maximal aerobic power
Sponsors
University Hospital, Lille
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
Cannabis consumer group: * Cannabis consumption \> 100 times in lifetime, last exposure \< 7 days, and recent exposure \> 10 times in the month. * Positive toxicological urine test for ∆-9-THC. * Having a cannabis use disorder according to the CAST. Healthy group: * Negative urine toxicological test for cannabis. * No regular cannabis use for more than 6 months once in a lifetime. * No cannabis consumption in the 6 months preceding the study.
Exclusion criteria
For all subjects : * Disorders of use of other substances (alcohol, cocaine, opioid, or synthetic drugs). * Alcohol consumption greater than 30g per day (averaged over one week) and/or alcohol abuse the week preceding the visit. * Under medical treatment. * Presence of diagnosed neurological disorders. * Diagnosis of a psychotic picture entering axis I, DSM-5. * Chronic progressive disease or in remission. * Body mass index \> 30 kg/m2 (i.e. presence of obesity).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma endocannabinoids levels (pmol/ml) | 2 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| regulating hormone of endocannabinoids (plasma levels of cortisol, ng/ml) | 2 weeks | — |
| Blood marker of neurogenesis and neuroplasticity (plasma levels and BDNF, pg/ml) | 2 weeks | — |
| change in cerebral muscular, oxygenation (HHB), (HbO2), (Hbtot) (arbitrary unit) | 2 weeks | — |
| Cognitive function (selective attention, stroop test) | 2 weeks | The stroop test can be used to measure a person's selective attention capacity |
| Oxygen consumption (VO2) (ml/min/kg) | 2 weeks | — |
Countries
France
Contacts
CONTACTOlivier Cottencin, MD,PhD
CONTACTFrancois-xavier Gamelin, PhD
Outcome results
None listed